Parfieniuk-Kowerda Anna, Jaroszewicz Jerzy, Łapiński Tadeusz W, Łucejko Mariusz, Maciaszek Magdalena, Świderska Magdalena, Grzeszczuk Anna, Naumnik Beata, Rowiński Mirosław, Flisiak Robert
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia, Bytom, Poland.
Arch Med Sci. 2018 Dec 5;17(3):675-681. doi: 10.5114/aoms.2018.79958. eCollection 2021.
The incidence of hepatitis E virus (HEV) infections in Poland is largely unknown. This study aimed to describe seroprevalence of markers of HEV infection among patients with immunodeficiency of diverse etiology and patients with advanced chronic liver diseases.
Four hundred fifty patients were enrolled; among them, 180 persons were solid organ transplant recipients, 90 patients were HIV-infected and 180 persons had confirmed liver cirrhosis of different etiology. Serum anti-HEV-IgG, IgM antibodies and HEV-antigen were detected by ELISA (Wantai, China).
In the group of transplant recipients, serum anti-HEV-IgG antibodies were detected in 40.6%, IgM in 1.1% and HEV-Ag in 2.8% of subjects. In the HIV-infected population 37.7% had anti-HEV-IgG, 1.1% had anti-HEV-IgM and none had HEV-Ag. Among patients with advanced chronic liver diseases the highest prevalence of anti-HEV-IgG was recorded in alcohol-related liver cirrhosis (52.1%) ( = 0.049). In the population of all liver cirrhotics anti-HEV-IgG seroprevalence was 48.3%, anti-HEV-IgM seroprevalence was 5.0% and HEV-Ag seroprevalence was 1.7%. Older age and male gender were significant risk factors associated with increased anti-HEV-IgG prevalence, = 0.0004 and = 0.02, respectively.
In this large cohort a high seroprevalence of anti-HEV-IgG was detected in comparison to other European countries, with the highest rates in patients with alcoholic liver disease and in transplant recipients.
波兰戊型肝炎病毒(HEV)感染的发病率很大程度上未知。本研究旨在描述不同病因免疫缺陷患者和晚期慢性肝病患者中HEV感染标志物的血清流行率。
纳入450例患者;其中,180例为实体器官移植受者,90例为HIV感染者,180例为确诊的不同病因肝硬化患者。采用酶联免疫吸附测定法(中国万泰)检测血清抗HEV-IgG、IgM抗体及HEV抗原。
在移植受者组中,40.6%的受试者检测到血清抗HEV-IgG抗体,1.1%检测到IgM,2.8%检测到HEV抗原。在HIV感染人群中,37.7%有抗HEV-IgG,1.1%有抗HEV-IgM,无人检测到HEV抗原。在晚期慢性肝病患者中,酒精性肝硬化患者抗HEV-IgG的患病率最高(52.1%)(P = 0.049)。在所有肝硬化患者人群中,抗HEV-IgG血清流行率为48.3%,抗HEV-IgM血清流行率为5.0%,HEV抗原血清流行率为1.7%。年龄较大和男性是与抗HEV-IgG患病率增加相关的显著危险因素,P值分别为0.0004和0.02。
与其他欧洲国家相比,在这个大型队列中检测到较高的抗HEV-IgG血清流行率,酒精性肝病患者和移植受者中的发生率最高。